141 related articles for article (PubMed ID: 17661736)
1. Lumiracoxib in the management of osteoarthritis and acute pain.
Bannwarth B; Bérenbaum F
Expert Opin Pharmacother; 2007 Jul; 8(10):1551-64. PubMed ID: 17661736
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.
Bannwarth B; Berenbaum F
Expert Opin Investig Drugs; 2005 Apr; 14(4):521-33. PubMed ID: 15882125
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
Farkouh ME; Greenberg JD; Jeger RV; Ramanathan K; Verheugt FW; Chesebro JH; Kirshner H; Hochman JS; Lay CL; Ruland S; Mellein B; Matchaba PT; Fuster V; Abramson SB
Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
[TBL] [Abstract][Full Text] [Related]
4. A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.
Stricker K; Yu S; Krammer G
BMC Musculoskelet Disord; 2008 Sep; 9():118. PubMed ID: 18778469
[TBL] [Abstract][Full Text] [Related]
5. Global gastrointestinal safety profile of etoricoxib and lumiracoxib.
Yuan Y; Hunt RH
Curr Pharm Des; 2007; 13(22):2237-47. PubMed ID: 17691997
[TBL] [Abstract][Full Text] [Related]
6. Clinical use and pharmacological properties of selective COX-2 inhibitors.
Shi S; Klotz U
Eur J Clin Pharmacol; 2008 Mar; 64(3):233-52. PubMed ID: 17999057
[TBL] [Abstract][Full Text] [Related]
7. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
[TBL] [Abstract][Full Text] [Related]
8. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
Hawkey CJ; Weinstein WM; Smalley W; Gitton X; Sallstig P; Stricker K; Krammer G; Mellein B; Richard D; Matchaba P
Gastroenterology; 2007 Jul; 133(1):57-64. PubMed ID: 17631131
[TBL] [Abstract][Full Text] [Related]
9. Lumiracoxib.
Buvanendran A; Barkin R
Drugs Today (Barc); 2007 Mar; 43(3):137-47. PubMed ID: 17380211
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
Hawkey CJ; Farkouh M; Gitton X; Ehrsam E; Huels J; Richardson P
Aliment Pharmacol Ther; 2004 Jul; 20(1):51-63. PubMed ID: 15225171
[TBL] [Abstract][Full Text] [Related]
12. Lumiracoxib.
Lyseng-Williamson KA; Curran MP
Drugs; 2004; 64(19):2237-46; discussion 2247-8. PubMed ID: 15456339
[TBL] [Abstract][Full Text] [Related]
13. COX-2 selective inhibitors in the treatment of osteoarthritis.
Laine L; White WB; Rostom A; Hochberg M
Semin Arthritis Rheum; 2008 Dec; 38(3):165-87. PubMed ID: 18177922
[TBL] [Abstract][Full Text] [Related]
14. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
Farkouh ME; Kirshner H; Harrington RA; Ruland S; Verheugt FW; Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Gimona A; Matchaba P; Hawkey CJ; Chesebro JH;
Lancet; 2004 Aug 21-27; 364(9435):675-84. PubMed ID: 15325832
[TBL] [Abstract][Full Text] [Related]
15. Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
Fleischmann R; Tannenbaum H; Patel NP; Notter M; Sallstig P; Reginster JY
BMC Musculoskelet Disord; 2008 Mar; 9():32. PubMed ID: 18328090
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
Hawkey CJ; Gitton X; Hoexter G; Richard D; Weinstein WM
Clin Gastroenterol Hepatol; 2006 Jan; 4(1):57-66. PubMed ID: 16431306
[TBL] [Abstract][Full Text] [Related]
17. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
Matheson AJ; Figgitt DP
Drugs; 2001; 61(6):833-65. PubMed ID: 11398914
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.
Rordorf CM; Choi L; Marshall P; Mangold JB
Clin Pharmacokinet; 2005; 44(12):1247-66. PubMed ID: 16372823
[TBL] [Abstract][Full Text] [Related]
19. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
